AI-driven Clairity Breast platform, now FDA-approved, predicts five-year breast cancer risk from mammograms, enhancing early ...

The startup received de novo authorization for the AI tool, the first of its kind that analyzes mammogram images to predict ...

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast ...

Bealmear accepted a four-month suspension, but he argues that the substance in question neither contained a banned substance, ...

Researchers at the University of Michigan Health Rogel Cancer Center identified a gene that plays a key role in prostate ...

The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...

ImmunityBio, Inc. today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a ...

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

Regularly consuming coffee during middle age may provide a health boost for women as they get older, according to a finding ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team ...

CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across ...